Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;26(7):678-687.
doi: 10.3348/kjr.2024.1202. Epub 2025 Jun 13.

Quantitative Analysis With Time-Dependent Diffusion MRI for Assessing WHO/ISUP Tumor Grade in Clear Cell Renal Cell Carcinoma

Affiliations

Quantitative Analysis With Time-Dependent Diffusion MRI for Assessing WHO/ISUP Tumor Grade in Clear Cell Renal Cell Carcinoma

Chunlei He et al. Korean J Radiol. 2025 Jul.

Abstract

Objective: To investigate the feasibility of time-dependent diffusion-weighted imaging (td-dMRI) in assessing the pathological World Health Organization/International Society of Urological Pathology (WHO/ISUP) grade of clear cell renal cell carcinoma (ccRCC).

Materials and methods: A total of 138 patients (median age, 58 years [interquartile range, 51-64 years]; 89 males) with surgically confirmed ccRCC, comprising 48 high-grade (WHO/ISUP grade III/IV) and 90 low-grade (WHO/ISUP grade I/II) tumors, were included in the study among patients who underwent preoperative td-dMRI for suspected RCC between May 2022 and May 2024. The td-dMRI microstructural parameters, including cell diameter (d), intracellular volume fraction (fin), cellularity, and extracellular diffusivities (Dex), were quantified using a two-compartment model. The solid tumor area was manually annotated to extract the mean values from each parameter map. We analyzed the differences in td-dMRI parameters between the high- and low-grade tumors and evaluated the ability of these parameters to distinguish between the two tumor groups. High-definition hematoxylin-and-eosin-stained slides were obtained from 92 patients. We assessed the correlation between td-dMRI parameters and pathologic nuclear fraction, which was quantified using an automated nucleus segmentation model (Hover-Net).

Results: Compared to high-grade tumors, low-grade tumors exhibited lower cellularity and fin and higher diameter and Dex. For differentiation between low- and high-grade ccRCC, the fin exhibited the highest diagnostic performance (areas under the receiver operating characteristic curve [AUC] = 0.943; 95% confidence interval, 0.906-0.980), followed by cellularity (AUC = 0.931; 0.887-0.976), Dex (AUC = 0.863; 0.800-0.926), and diameter (AUC = 0.690; 0.596-0.784). The nuclei on pathology slides were automatically segmented, and the nuclear fraction exhibited a moderate correlation with fin (r = 0.65, P < 0.001).

Conclusion: td-dMRI parameters show potential for assessing pathological WHO/ISUP grades and may serve as promising noninvasive biomarkers for characterizing RCC.

Keywords: Diffusion weighted image; Renal cell carcinoma; Time-dependent diffusion; WHO/ISUP grade.

PubMed Disclaimer

Conflict of interest statement

The authors of this manuscript declare relationships with the following company: Philips Healthcare. One of our authors (Xiaoyong Zhang) is an employee of Philips Healthcare. This author only provided technical support and did not have control over the data at any point during the study.

Figures

Fig. 1
Fig. 1. The inclusion and exclusion flowchart of the participants. RCC = renal cell carcinoma, OGSE = oscillating gradient spin-echo, ccRCC = clear cell renal cell carcinoma, T2WI = T2-weighted imaging
Fig. 2
Fig. 2. Schematic illustration of the time-dependent diffusion MRI model fitting process. OGSE = oscillating gradient spin-echo, PGSE = pulsed gradient spin-echo, fin = intracellular volume fraction, Sin = intracellular diffusion MRI signal, Sex = extracellular diffusion MRI signal, Dex = extracellular diffusivity, d = diameter
Fig. 3
Fig. 3. The quantitative mappings of T2WI, Dex, cellularity, d, fin, D0Hz, D17Hz, D33Hz for patients with WHO/ISUP 1-4. The units for Dex, D0Hz, D17Hz, and D33Hz were µm2/ms; the d was µm, and cellularity was µm-1. T2WI = T2-weighted imaging, Dex = extracellular diffusivity, d = diameter, fin = intracellular volume fraction, D0Hz = diffusivity at 0 Hz, D17Hz = diffusivity at 17 Hz, D33Hz = diffusivity at 33 Hz, WHO/ISUP = World Health Organization/International Society of Urological Pathology
Fig. 4
Fig. 4. The violin boxplots show time-dependent diffusion MRI-based Dex, cellularity, fin, d, D0Hz, D17Hz, D33Hz from high- and low-grade clear cell renal cell carcinomas. *P < 0.0001, P < 0.01, P < 0.001, §P < 0.05. Dex = extracellular diffusivity, fin = intracellular volume fraction, d = diameter, D0Hz = diffusivity at 0 Hz, D17Hz = diffusivity at 17 Hz, D33Hz = diffusivity at 33 Hz, WHO/ISUP = World Health Organization/International Society of Urological Pathology
Fig. 5
Fig. 5. The receiver operating characteristic curves of quantitative parameters from time-dependent diffusion MRI in differentiating low- from high-grade clear cell renal cell carcinomas. Dex = extracellular diffusivity, fin = intracellular volume fraction
Fig. 6
Fig. 6. The workflow of pathology validation. A: A rectangular ROI was placed on the hematoxylin and eosin staining slice to cover the solid area as large as possible. B: The ROI was separated into 2048 × 2048 pixel-sized patches. C: The patches were input into the open-source pre-trained Hover-Net to get the nuclei segmentation. The nuclear fraction on pathology was calculated as the ratio of the sum of the nuclei area to the sum of the tissue area across all patches in 1 slide. D: The correlation map between fin from the IMPULSED model and the nuclear fraction on pathology. ROI = region of interest, fin = intracellular volume fraction, IMPULSED = imaging microstructural parameters using limited spectrally edited diffusion

Similar articles

References

    1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12–49. - PubMed
    1. Bukavina L, Bensalah K, Bray F, Carlo M, Challacombe B, Karam JA, et al. Epidemiology of renal cell carcinoma: 2022 update. Eur Urol. 2022;82:529–542. - PubMed
    1. Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Ljungberg B, et al. The 2022 updated European Association of Urology guidelines on the use of adjuvant immune checkpoint inhibitor therapy for renal cell carcinoma. Eur Urol. 2023;83:10–14. - PubMed
    1. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70:93–105. - PubMed
    1. Liu N, Gan W, Qu F, Wang Z, Zhuang W, Agizamhan S, et al. Does the Fuhrman or World Health Organization/International Society of Urological Pathology grading system apply to the Xp11.2 translocation renal cell carcinoma?: A 10-year single-center study. Am J Pathol. 2018;188:929–936. - PMC - PubMed